KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.

返回会议原文

返回会议

Mustafa Özdoğan, MD· @ozdogan_md · X·2026-10-26 00:01· 1 天前评分70

正文 · 机器翻译

KRAScendo 1：KRAS G12C 靶向治疗领域首次头对头比较，在 ESMO 上报告并发表于 NEJM。

这会改变二线标准治疗吗？

#ESMO26 #Oncology #LungCancer

107 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Mustafa Özdoğan, MD · x.com